Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval.
Emily A. King, J. Wade Davis, Jacob F. Degner
Updated pipeline and genetic data confirm genetically supported drug targets succeed more often; Mendelian (OMIM) support replicates prospectively, while GWAS support is weaker unless coding-linked.